Clues Pointing TO This Diagnosis

Young woman (31 years old) with two years of relapsing-remitting multisystem complaints — SLEpredominantly affects women of reproductive age and is characterized by fluctuating multiorgan involvement
Inflammatory arthritis of the fingers with morning stiffness — inflammatory joint pain/synovitis in ≥2 joints with morning stiffness is a weighted musculoskeletal criterion
Malar ("butterfly") rash over the cheeks — this classic fixed erythema over the malar eminences is acute cutaneous lupus, a heavily weighted mucocutaneous criterion
Photosensitivity (sun makes symptoms worse) — photosensitive skin disease is characteristic of cutaneous lupus
Non-scarring alopecia (excess hair loss in the shower) — non-scarring alopecia is a recognized mucocutaneous criterion
Persistent fatigue — one of the most common constitutional symptoms of SLE
Positive ANA at high titer, speckled pattern — a positive ANA (≥1:80) is the obligatory entry criterion, and specificity rises with higher titers
Elevated anti–double-stranded DNA — anti-dsDNA is ~97% specific for SLE and strongly supports the diagnosis
Low complement (C3 and C4) — hypocomplementemia is an immunologic criterion and reflects active disease
Proteinuria on urinalysis with biopsy-confirmed lupus nephritis — renal involvement (proteinuria >0.5 g/day) with biopsy-proven class III (focal proliferative) disease is the highest-weighted renal criterion

Why It's NOT the Similar Diseases

NOT rheumatoid arthritis — Carolyn's arthritis is nonerosive and accompanied by malar rash, photosensitivity, nephritis, low complement, and anti-dsDNA, a multisystem picture with SLE-specific serologies rather than the erosive, RF/anti-CCP–positive symmetric arthritis of RA
NOT undifferentiated or mixed connective tissue disease — she meets full criteria for SLE with anti-dsDNA and lupus nephritis, rather than an incomplete picture or an anti-RNP–defined overlap syndrome
NOT drug-induced lupus — there is no offending medication and drug-induced lupus rarely causes significant nephritis or high anti-dsDNA, instead being associated with anti-histone antibodies and resolving after drug withdrawal
NOT primary Sjögren syndrome or another ANA-positive rheumatic disease — a positive ANA is nonspecific, but her anti-dsDNA, hypocomplementemia, malar rash, and proliferative lupus nephritis point specifically to SLE
NOT a chronic infection (e.g., viral hepatitis, parvovirus, syphilis, endocarditis) — these mimics can produce constitutional symptoms and a positive ANA but do not produce anti-dsDNA with biopsy-proven immune-complex lupus nephritis

Differential Diagnosis List

Rheumatoid arthritis — ruled out by malar rash, photosensitivity, lupus nephritis, low complement, and anti-dsDNA rather than an erosive RF/anti-CCP arthritis
Mixed/undifferentiated connective tissue disease — ruled out by meeting full SLE criteria with anti-dsDNA and proliferative lupus nephritis
Drug-induced lupus — ruled out by absence of a culprit drug and the presence of nephritis with high anti-dsDNA
Primary Sjögren syndrome — ruled out by SLE-specific serologies (anti-dsDNA, low complement) and biopsy-proven lupus nephritis
Chronic infection (viral hepatitis, parvovirus, syphilis, endocarditis) — ruled out by anti-dsDNA positivity and immune-complex lupus nephritis on biopsy

Key Distinguishing Test

There is no single diagnostic test; SLE is a clinical diagnosis supported by serologies, with a positive ANA (≥1:80) as the required entry point and anti-dsDNA (~97% specific) plus low C3/C4 strongly confirming the diagnosis in the right clinical setting.
When renal involvement is suspected, a percutaneous kidney biopsy is the gold standard: it confirms lupus nephritis, assigns the ISN/RPS class (Carolyn's class III, focal proliferative), and grades activity/chronicity to direct therapy.

Board Note

Classic profile: reproductive-age woman with fatigue, inflammatory arthritis, malar rash, photosensitivity, and cytopenias; screen with ANA, and if positive pursue anti-dsDNA, anti-Smith, complement (C3/C4), CBC, and urinalysis with protein-to-creatinine ratio
Anti-dsDNA titers and complement levels are used to monitor disease activity over time, while anti-Smith is highly specific but less sensitive
Hydroxychloroquine is foundational for essentially all patients (unless contraindicated) and reduces flares; baseline and periodic ophthalmologic screening is required for retinal toxicity
Glucocorticoids control active disease but should be tapered to the lowest possible dose (maintenance ≤5 mg/day prednisone equivalent), adding steroid-sparing immunosuppressants to limit toxicity
Proliferative lupus nephritis (class III/IV) is treated with glucocorticoids plus mycophenolate-based regimens (often combined with belimumab or a calcineurin inhibitor), and therapy should begin as soon as possible after diagnosis
When to refer: any suspicion of SLE warrants rheumatology involvement, and suspected lupus nephritis (proteinuria >0.5 g/day, active sediment, or unexplained rising creatinine) warrants prompt nephrology referral for kidney biopsy
Counsel on strict photoprotection (broad-spectrum SPF, sun-protective clothing), cardiovascular risk reduction, vaccination, and pregnancy planning, since flares and antiphospholipid antibodies affect maternal-fetal outcomes
Both parts below are grounded in current sources: DSM-5/DSM-5-TR criteria as summarized in NEJM and by the American Psychiatric Association, the 2022 AAFP schizophrenia review, the 2023 VA/DoD First-Episode Psychosis and Schizophrenia guideline, and consensus definitions of treatment-resistant schizophrenia.
─── PART 1 — DECODER SHEET ───

“Carolyn’s Story”